| Description |
UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels with minimal effect on p21 protein stability. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].
|
| Related Catalog |
|
| In Vitro |
UC2288 (0-10 μM; 24 hours) decreases p21 protein level, but has no effects on other proteins[1]. UC2288 (0-10 μM; 24 hours) decreases p21 mRNA expression transcriptionally or post-transcriptionally but independently of p53[1]. Western Blot Analysis[1] Cell Line: HK2 (normal kidney), 786-O (RCC), Caki-1 (RCC), ACHN (RCC) and HEY (ovarian cancer) cells Concentration: 0 μM; 1 μM; 3 μM; 10 μM Incubation Time: 24 hours Result: Decreased p21 protein expression. RT-PCR[1] Cell Line: p53-mutant RCC cell line 786-O Concentration: 10 μM Incubation Time: 24 hours Result: Decreased p21 mRNA independent of p53 expression.
|
| References |
[1]. Hiromi I Wettersten, et al. A Novel p21 Attenuator Which Is Structurally Related to Sorafenib. Cancer Biol Ther. 2013 Mar;14(3):278-85.
|
